What is the ROE (Return on Equity) of Dexcom this year?
The ROE of Dexcom this year is 0.26 undefined.
Dexcom ROE 2024
Dexcom ROE
0.26
Ticker
DXCM
ISIN
US2521311074
WKN
A0D9T1
In 2024, Dexcom's return on equity (ROE) was 0.26, a 63.55% increase from the 0.16 ROE in the previous year.
Dexcom Aktienanalyse
What does Dexcom do?
Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Dexcom's Return on Equity (ROE)
Dexcom's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Dexcom's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Dexcom's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Dexcom’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Dexcom Stock
How has the Return on Equity (ROE) of Dexcom developed compared to the previous year?
The ROE of Dexcom has increased by 63.55% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Dexcom?
A high ROE indicates that Dexcom generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Dexcom?
A low ROE can indicate that Dexcom is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Dexcom affect the company?
A change in ROE (Return on Equity) of Dexcom can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Dexcom?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Dexcom?
Some factors that can influence Dexcom's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Dexcom pay?
Over the past 12 months, Dexcom paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dexcom is expected to pay a dividend of 0 USD.
What is the dividend yield of Dexcom?
The current dividend yield of Dexcom is .
When does Dexcom pay dividends?
Dexcom pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Dexcom?
Dexcom paid dividends every year for the past 0 years.
What is the dividend of Dexcom?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Dexcom located?
Dexcom is assigned to the 'Health' sector.
Wann musste ich die Aktien von Dexcom kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Dexcom from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.
When did Dexcom pay the last dividend?
The last dividend was paid out on 6/19/2024.
What was the dividend of Dexcom in the year 2023?
In the year 2023, Dexcom distributed 0 USD as dividends.
In which currency does Dexcom pay out the dividend?
The dividends of Dexcom are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Dexcom stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Dexcom
Our stock analysis for Dexcom Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
